Newlink Genetics reported $3.92M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agenus AGEN:US USD 18.1M 809K
Bristol Myers Squibb BMY:US USD 1.93B 147M
Capricor Therapeutics CAPR:US USD 2.56M 208.29K
Celldex Therapeutics CLDX:US USD 6.53M 623K
Eli Lilly And LLY:US USD 1.61B 10.9M
Idera Pharmaceuticals IDRA:US USD 2.27M 391K
Intrexon XON:US USD 10.14M 2.53M
Merk MRK:US USD 2.47B 13M
Nektar Therapeutics NKTR:US USD 22.53M 1.09M
Newlink Genetics NLNK:US USD 3.92M 236K
Pfizer PFE:US USD 3.54B 345M
Prothena PRTA:US USD 11.99M 963K
Sarepta Therapeutics SRPT:US USD 104.79M 49.53M
Vascular Biogenics VBLT:US USD 3.75M 823K
YTE INCY:US USD 266.46M 13.18M